Cell therapy weekly: US FDA warns stem cell clinic over marketing of human stem cell products

This week: the US FDA has issued a letter to a stem cell clinic over their marketing of intrathecal and intravenous injections of human stem cell-based products for serious conditions; a CAR-T therapy demonstrates a long remission period (up to 5 years) in patients with relapsed B-cell lymphoma; an allogeneic cell therapy product, termed ALLOB, shows positive 24-month follow-up results; and the EpiMOGRIFY platform has been announced to identify epigenetic switches driving cell identity and cell maintenance. The news highlights: US FDA issues warning to stem cell clinic over marketing of human stem cell products CAR-T therapy demonstrates long remission...